Answering the questions of journalists after the meeting of the health ministers of EU countries with video conferencing, Stella Kyriakides, the member of the EU Commission responsible for health, emphasized that they are competing against time in the fight against the new type of Corona virus (Covid-19) outbreak.
“However, we are still calling on member states to use all the doses they have available,” said Kyriakides. said.
Stressing that some countries have used all of the vaccines delivered, in others this rate is around 50 percent, Kyriakides said:
“Every dose counts. Each dose is a shield for healthcare workers, the elderly, vulnerable groups. Some member countries keep what they have for the second dose. We see this in numbers. But there are differences in the number of vaccinations. This should be expedited in a coordinated way. Deliveries are expected to increase in the coming months. and speeding up vaccinations is important, so we urge each member to use all the doses available to them. “
ONE-IN-4 OF DOSE IS WAITED IN EU COUNTRIES
According to the data of the European Center for Disease Prevention and Control (ECDC), a total of 62.3 million doses of vaccine have been sent to EU countries and non-EU countries Iceland, Liechtenstein and Norway, but 48.1 million of them have been used.
14.8 million of these are AstraZeneca vaccine, whose use in many EU countries is discontinued for precautionary reasons due to suspicion of blood clotting.
While the amount of BioNTech-Pfizer vaccines was 42.3 million doses, Moderna’s vaccines were 3.6 million doses, a small amount of Chinese and Russian vaccines reached EU countries. Hungary and Slovakia are known to have received these vaccines, which have not yet been approved in the EU.
Italy and Lithuania were the only two to use all of the vaccines, according to the ECDC’s numbers. Three quarters of vaccines were used in most EU countries. The European countries that use the least vaccines appear to be Liechtenstein with 56 percent and Luxembourg with 58 percent.
As of March 16, the rate of use of the doses distributed throughout the EU is 77 percent.